Protagonist Therapeutics, Inc
SEC CIK 1377121 · PTGX · last insider filing 2026-06-25
Directors (from insider filings)
| Name | Capacity as filed | Filings |
|---|---|---|
| Waddill William D. | Director | filed 2016 - 2026 |
| Patel Dinesh V PH D | Director · President and CEO | filed 2016 - 2026 |
| Giraudo Bryan | Director | filed 2018 - 2026 |
| Selick Harold E | Director | filed 2016 - 2026 |
| Williams Lewis T | Director | filed 2017 - 2026 |
| O'Dowd Sarah A | Director | filed 2020 - 2026 |
| Swisher Daniel N JR | Director | filed 2023 - 2023 |
| Noonberg Sarah B. | Director | filed 2017 - 2023 |
| Khosla Chaitan PHD | Director | filed 2016 - 2020 |
| Shanafelt Armen | Director | filed 2016 - 2018 |
| Canaan X L.P. | Director | filed 2016 - 2018 |
| Canaan Partners X LLC | Director | filed 2016 - 2018 |
| Papanek Julie | Director | filed 2016 - 2017 |
Officers (from insider filings)
| Name | Title as filed | Filings |
|---|---|---|
| Ali Asif | Chief Financial Officer | filed 2022 - 2026 |
| Molina Arturo MD | Chief Medical Officer | filed 2022 - 2026 |
| Gupta Suneel | EVP Clinical Operations | filed 2019 - 2024 |
| Liu David Y | Chief Scientific Officer | filed 2016 - 2022 |
| Kalkofen Donald A. | Chief Financial Officer | filed 2019 - 2022 |
| Saks Samuel R | Chief Medical Officer | filed 2018 - 2021 |
| Shames Richard S. | Chief Medical Officer | filed 2016 - 2019 |
| Murphy Niall | VP, Controller, Interim PAO | filed 2019 - 2019 |
| O'Neil Thomas P. | Chief Financial Officer | filed 2016 - 2018 |
| Hodder William A | Sr. VP - Corporate Development | filed 2016 - 2016 |
About this record
From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.
Source: SEC Insider Transactions Data Sets (Forms 3/4/5), US Federal Government public domain.